Significantly expands scope of patent coverage for Company’s proprietary drug delivery systems to now include transdermal deliveryPatent expected to issue...
NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced...
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes,...
CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial...
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...
American Oncology Network (AON) and Vantage Health Technologies Partner to Improve Cancer Patient Outcomes with AI-enabled Value-Based Care Platform Todd...
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome...
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous...
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA)...
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its...
- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved...
NEW HYDE PARK, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- CareMed, a leading independent Specialty Pharmacy, has been selected by...
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in...
Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and...
CLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company has resubmitted its...
SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human...
eValuator Quality Module provides real-time risk scoring and quality measurement impactATLANTA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- – Streamline Health...
– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net...